Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways

JNK signaling in cancer cell survival

(2019) Qinghua Wu et al.   MEDICINAL RESEARCH REVIEWS

Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway

(2019) Xiaopei Tong et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

(2019) Zi-Yi Xu et al.   OncoTargets and Therapy

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

(2019) Daphné Morel et al.   Nature Reviews Clinical Oncology

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2

(2018) Rastislav Bahleda et al.   BRITISH JOURNAL OF CANCER

Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors

(2018) Mahaveer Singh et al.   DRUG DISCOVERY TODAY

E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer

(2018) Shuo Wang et al.   FEBS LETTERS

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

(2018) Ines De Pauw et al.   Molecular Oncology

Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer

(2018) Lorenzo Stramucci et al.   Cancers

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

(2018) Xiaoyun Lu et al.   MEDICINAL RESEARCH REVIEWS

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

(2018) Gonzalo Recondo et al.   Nature Reviews Clinical Oncology

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis

(2018) A. Camerini et al.   Clinical & Translational Oncology

IL-17A/IL-17RA promotes invasion and activates MMP-2 and MMP-9 expression via p38 MAPK signaling pathway in non-small cell lung cancer

(2018) Zhenhua Wu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The ERK and JNK pathways in the regulation of metabolic reprogramming

(2018) Salvatore Papa et al.   ONCOGENE

Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy

(2018) Meghan Leary et al.   Cancers

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

(2018) Tatsuya Nagano et al.   Cells

Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways

(2017) Zhen Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer

(2017) C Hardin et al.   EXPERT OPINION ON PHARMACOTHERAPY

Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer

(2017) Jaafar Bennouna   Future Oncology

P38 pathway as a key downstream signal of connective tissue growth factor to regulate metastatic potential in non-small-cell lung cancer

(2016) Shinichiro Kato et al.   CANCER SCIENCE

Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress

(2016) Jaafar Bennouna et al.   Future Oncology

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

(2016) Nadia Harbeck et al.   LANCET ONCOLOGY

Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer

(2016) Francesco Perri et al.   OncoTargets and Therapy

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer

(2015) Hirofumi Mukai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

(2015) Javier Cortés et al.   LANCET ONCOLOGY

PI3K/Akt-mediated regulation of p53 in cancer

(2014) Aswin G. Abraham et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Targeting RAS–ERK signalling in cancer: promises and challenges

(2014) Ahmed A. Samatar et al.   NATURE REVIEWS DRUG DISCOVERY

Afatinib—new therapy option for EGFR-mutant lung cancer

(2013) Helena A. Yu et al.   Nature Reviews Clinical Oncology

p38 mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients

(2012) David Planchard et al.   CANCER

Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Sensitize Lung Cancer Cells to Etoposide

(2011) M.-S. Tsai et al.   MOLECULAR CANCER THERAPEUTICS

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcriptional down-regulation of Bcl-2 by vinorelbine: Identification of a novel binding site of p53 on Bcl-2 promoter

(2009) Véronique Bourgarel-Rey et al.   BIOCHEMICAL PHARMACOLOGY

The genetics of the p53 pathway, apoptosis and cancer therapy

(2008) Alexei Vazquez et al.   NATURE REVIEWS DRUG DISCOVERY